Vascular risk factors and Alzheimer’s disease pathogenesis

Are conventional pharmacological approaches protective for cognitive decline progression?

Apostolos Safouris, Theodora Psaltopoulou, Theodoros N. Sergentanis, Eleni Boutati, Elisabeth Kapaki, Georgios Tsivgoulis

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Alzheimer’s disease (AD) is the most common cause of dementia, accounting for more than half of cases with cognitive impairment. With numbers of patients expected to rise sharply over the following years in parallel with the ageing of population, there is intense clinical interest in discovering modifiable risk factors that may contribute to the increasing prevalence of AD. Accumulating data from in vitro and epidemiological studies have highlighted the vascular component of AD and raised hope that treatment of vascular risk factors could eventually lead to primary prevention of AD. Among all the possible pathologic processes that have been tested for an association with AD, diabetes, hypertension and dyslipidemia are the most prominent. Here, we will briefly review the data highlighting a potential correlation of these diseases with AD. Then, we will present observational studies and clinical trials that assessed the impact of their respective approved medical therapies on AD incidence. We conclude by providing clinical information for the physician on potentially effective and non-effective medical treatments. Further research is ongoing and time will show whether AD will cease to be considered a pure, non-preventable neurodegenerative process or whether vascular risk factor management may also result in primary AD prevention.

Original languageEnglish (US)
Pages (from-to)257-269
Number of pages13
JournalCNS and Neurological Disorders - Drug Targets
Volume14
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Alzheimer Disease
Pharmacology
vascular factor
Cognitive Dysfunction
Risk Management
Pathologic Processes
Primary Prevention
Dyslipidemias
Observational Studies
Blood Vessels
Dementia
Epidemiologic Studies
Therapeutics
Clinical Trials
Hypertension
Physicians
Incidence
Research
Population

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Pharmacology

Cite this

Vascular risk factors and Alzheimer’s disease pathogenesis : Are conventional pharmacological approaches protective for cognitive decline progression? / Safouris, Apostolos; Psaltopoulou, Theodora; Sergentanis, Theodoros N.; Boutati, Eleni; Kapaki, Elisabeth; Tsivgoulis, Georgios.

In: CNS and Neurological Disorders - Drug Targets, Vol. 14, No. 2, 01.01.2015, p. 257-269.

Research output: Contribution to journalArticle

Safouris, Apostolos ; Psaltopoulou, Theodora ; Sergentanis, Theodoros N. ; Boutati, Eleni ; Kapaki, Elisabeth ; Tsivgoulis, Georgios. / Vascular risk factors and Alzheimer’s disease pathogenesis : Are conventional pharmacological approaches protective for cognitive decline progression?. In: CNS and Neurological Disorders - Drug Targets. 2015 ; Vol. 14, No. 2. pp. 257-269.
@article{6ad94894b00d42ac8a85b6ec738cb0b0,
title = "Vascular risk factors and Alzheimer’s disease pathogenesis: Are conventional pharmacological approaches protective for cognitive decline progression?",
abstract = "Alzheimer’s disease (AD) is the most common cause of dementia, accounting for more than half of cases with cognitive impairment. With numbers of patients expected to rise sharply over the following years in parallel with the ageing of population, there is intense clinical interest in discovering modifiable risk factors that may contribute to the increasing prevalence of AD. Accumulating data from in vitro and epidemiological studies have highlighted the vascular component of AD and raised hope that treatment of vascular risk factors could eventually lead to primary prevention of AD. Among all the possible pathologic processes that have been tested for an association with AD, diabetes, hypertension and dyslipidemia are the most prominent. Here, we will briefly review the data highlighting a potential correlation of these diseases with AD. Then, we will present observational studies and clinical trials that assessed the impact of their respective approved medical therapies on AD incidence. We conclude by providing clinical information for the physician on potentially effective and non-effective medical treatments. Further research is ongoing and time will show whether AD will cease to be considered a pure, non-preventable neurodegenerative process or whether vascular risk factor management may also result in primary AD prevention.",
author = "Apostolos Safouris and Theodora Psaltopoulou and Sergentanis, {Theodoros N.} and Eleni Boutati and Elisabeth Kapaki and Georgios Tsivgoulis",
year = "2015",
month = "1",
day = "1",
doi = "10.2174/1871527314666150217123147",
language = "English (US)",
volume = "14",
pages = "257--269",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Vascular risk factors and Alzheimer’s disease pathogenesis

T2 - Are conventional pharmacological approaches protective for cognitive decline progression?

AU - Safouris, Apostolos

AU - Psaltopoulou, Theodora

AU - Sergentanis, Theodoros N.

AU - Boutati, Eleni

AU - Kapaki, Elisabeth

AU - Tsivgoulis, Georgios

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Alzheimer’s disease (AD) is the most common cause of dementia, accounting for more than half of cases with cognitive impairment. With numbers of patients expected to rise sharply over the following years in parallel with the ageing of population, there is intense clinical interest in discovering modifiable risk factors that may contribute to the increasing prevalence of AD. Accumulating data from in vitro and epidemiological studies have highlighted the vascular component of AD and raised hope that treatment of vascular risk factors could eventually lead to primary prevention of AD. Among all the possible pathologic processes that have been tested for an association with AD, diabetes, hypertension and dyslipidemia are the most prominent. Here, we will briefly review the data highlighting a potential correlation of these diseases with AD. Then, we will present observational studies and clinical trials that assessed the impact of their respective approved medical therapies on AD incidence. We conclude by providing clinical information for the physician on potentially effective and non-effective medical treatments. Further research is ongoing and time will show whether AD will cease to be considered a pure, non-preventable neurodegenerative process or whether vascular risk factor management may also result in primary AD prevention.

AB - Alzheimer’s disease (AD) is the most common cause of dementia, accounting for more than half of cases with cognitive impairment. With numbers of patients expected to rise sharply over the following years in parallel with the ageing of population, there is intense clinical interest in discovering modifiable risk factors that may contribute to the increasing prevalence of AD. Accumulating data from in vitro and epidemiological studies have highlighted the vascular component of AD and raised hope that treatment of vascular risk factors could eventually lead to primary prevention of AD. Among all the possible pathologic processes that have been tested for an association with AD, diabetes, hypertension and dyslipidemia are the most prominent. Here, we will briefly review the data highlighting a potential correlation of these diseases with AD. Then, we will present observational studies and clinical trials that assessed the impact of their respective approved medical therapies on AD incidence. We conclude by providing clinical information for the physician on potentially effective and non-effective medical treatments. Further research is ongoing and time will show whether AD will cease to be considered a pure, non-preventable neurodegenerative process or whether vascular risk factor management may also result in primary AD prevention.

UR - http://www.scopus.com/inward/record.url?scp=84930904434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930904434&partnerID=8YFLogxK

U2 - 10.2174/1871527314666150217123147

DO - 10.2174/1871527314666150217123147

M3 - Article

VL - 14

SP - 257

EP - 269

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 2

ER -